Phio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family Office

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) recently announced its participation in a fireside chat with Force Family Office, scheduled for March 18, 2026. The event will feature CEO Robert Bitterman discussing the company's proprietary INTASYL gene silencing technology and its application in treating skin cancer, specifically cutaneous squamous cell carcinoma (cSCC), melanoma, and Merkel cell carcinoma. Phio's lead clinical candidate, PH-762, is currently undergoing a Phase 1b trial, which has reported a pathological response rate of approximately 65% across all dosing cohorts, with an impressive 85% response rate in the highest-dose cohort. This announcement comes at a time when the company is actively engaging with the FDA regarding the next stages of clinical development, targeted for the second quarter of 2026.

Phio Pharmaceuticals, based in King of Prussia, Pennsylvania, is a clinical-stage biopharmaceutical company focused on immuno-oncology therapeutics. The company's INTASYL platform aims to enhance the immune system's ability to combat cancer by silencing the PD-1 gene, which plays a significant role in the progression of various cancers. The Phase 1b trial, which includes 22 patients across five dose-escalation cohorts, has not reported any dose-limiting toxicities or serious adverse events, indicating a favorable safety profile for PH-762. This positive clinical data is crucial as it positions Phio to potentially advance its product candidate toward regulatory approval, contingent on successful FDA engagement.

As of the latest disclosures, Phio Pharmaceuticals has a market capitalization of approximately USD 30 million, with cash and cash equivalents projected to sustain operations into the first half of 2027. This financial position suggests that the company has a reasonable runway to continue its clinical development activities without immediate need for additional capital. However, the reliance on existing cash reserves raises questions about the potential for future dilution if the company must raise funds to support its ongoing trials and operational expenses. The absence of significant debt further strengthens its financial position, allowing for flexibility in navigating the upcoming phases of clinical development.

In terms of valuation, Phio's current market capitalization places it within the micro-cap tier of biopharmaceutical companies. A comparative analysis with direct peers in the same sector reveals that Phio's valuation metrics are relatively attractive. For instance, companies such as Athenex, Inc. (NASDAQ: ATNX) and Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) are similarly sized and engaged in the development of innovative cancer therapies. Athenex has a market cap of approximately USD 40 million, while Iovance is around USD 50 million. Both companies have been involved in advanced clinical trials, with Iovance focusing on cell therapy for cancer treatment, which presents a different approach compared to Phio's gene silencing technology. The valuation metrics, such as enterprise value per clinical candidate, indicate that Phio may be undervalued relative to its peers, especially given the promising clinical data from its Phase 1b trial.

Phio's execution track record appears solid, with the company successfully advancing its clinical programs without significant delays or setbacks. The reported pathological response rates in the ongoing trial are encouraging and align with the company's strategic focus on developing non-surgical treatments for skin cancers. However, the upcoming FDA engagement poses a critical risk; any delays or unfavorable feedback from the regulatory body could hinder the company's progress and impact its valuation. Additionally, the competitive landscape in the immuno-oncology space is intensifying, with numerous companies vying for market share in the treatment of skin cancers. This competitive pressure could affect Phio's ability to secure partnerships or funding in the future.

The next measurable catalyst for Phio Pharmaceuticals is the anticipated FDA engagement regarding the next stages of clinical development for PH-762, expected in the second quarter of 2026. This interaction will be pivotal in determining the future trajectory of the company's clinical programs and could significantly influence investor sentiment. Should the FDA provide favorable guidance, it may bolster Phio's position in the market and enhance its valuation prospects.

In conclusion, Phio Pharmaceuticals' recent announcement regarding its participation in the fireside chat and the positive clinical data from its Phase 1b trial represents a significant step forward for the company. The promising response rates and the absence of serious adverse events underscore the potential of its INTASYL technology in treating skin cancers. While the company's financial position appears stable with a sufficient cash runway, the reliance on existing funds raises concerns about future dilution risks. The upcoming FDA engagement will be a crucial determinant of the company's future success. Overall, this announcement can be classified as significant, as it not only highlights the progress of Phio's clinical programs but also sets the stage for potential advancements in its regulatory pathway and market positioning.

Key insights

• ●PH-762 shows 65% pathological response rate in Phase 1b trial.
• ●Cash reserves projected to last into H1 2027.
• ●FDA engagement expected in Q2 2026.

Disagree with this article?